Rigel Pharmaceuticals (RIGL) Stock Overview
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RIGL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Rigel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.58 |
| 52 Week High | US$43.72 |
| 52 Week Low | US$13.91 |
| Beta | 1.2 |
| 1 Month Change | 10.65% |
| 3 Month Change | 39.30% |
| 1 Year Change | 122.39% |
| 3 Year Change | 326.76% |
| 5 Year Change | 20.53% |
| Change since IPO | -95.06% |
Recent News & Updates
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Sep 26Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Sep 25
Recent updates
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Sep 26Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Sep 25Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Sep 25Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
Sep 03Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
Aug 06Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
May 15Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 09Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 02Rigel Looks Interesting, But Let's Wait For A Lower Price
Mar 11
Advancing Pipeline And Partnerships Will Drive Future Success
Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE.Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%
Feb 06Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Dec 20Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Shareholder Returns
| RIGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.4% | 2.8% | -0.2% |
| 1Y | 122.4% | 4.0% | 20.3% |
Return vs Industry: RIGL exceeded the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: RIGL exceeded the US Market which returned 20.1% over the past year.
Price Volatility
| RIGL volatility | |
|---|---|
| RIGL Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RIGL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RIGL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 163 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
Rigel Pharmaceuticals, Inc. Fundamentals Summary
| RIGL fundamental statistics | |
|---|---|
| Market cap | US$566.46m |
| Earnings (TTM) | US$97.82m |
| Revenue (TTM) | US$267.92m |
Is RIGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RIGL income statement (TTM) | |
|---|---|
| Revenue | US$267.92m |
| Cost of Revenue | US$46.11m |
| Gross Profit | US$221.81m |
| Other Expenses | US$123.99m |
| Earnings | US$97.82m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 04, 2025
| Earnings per share (EPS) | 5.45 |
| Gross Margin | 82.79% |
| Net Profit Margin | 36.51% |
| Debt/Equity Ratio | 73.0% |
How did RIGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 04:49 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rigel Pharmaceuticals, Inc. is covered by 22 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| Clarence Powell | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets Equity Research |